ICON plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and ACRONET Corporation, one of Japan’s largest CROs, today announced they have signed an alliance agreement. Through the agreement, ICON and ACRONET will collaborate to offer global and Japanese pharmaceutical clients a full range of clinical development capabilities to manage trials on a regional or global basis.
With headquarters in Tokyo and additional offices in Osaka, Fukuoka and New York, ACRONET employs around 500 clinical development professionals. ICON has been operational in Japan since 1995 and offers a wide range of clinical development services and contract staffing from its offices in Tokyo and Osaka.
Commenting on the alliance, Alan Morgan, ICON’s Group President, Clinical Research Services, said, “Japan is an important centre for clinical research and ICON has a well established presence there. Recent changes in the regulatory landscape mean that an increasing number of Japanese based pharmaceutical companies are looking to run development projects on both a domestic and pan regional basis. The alliance between ICON and ACRONET will benefit clients, who can be assured of a wider range of quality drug development services alongside truly global expertise.”
Shogo Nakamori, ACRONET’s President & CEO, said, “The number of global clinical trials involving the triad regions of US, EU and Japan has increased gradually in recent years and this trend will continue to accelerate. This is one of the challenging areas for the Japanese pharmaceutical industry and ACRONET is now ready to contribute and support the above challenging areas through this alliance with ICON.”ICON is one of the leading providers of contract development services in Asia-Pacific and employs approximately 1,000 staff in the region. About ICON plc ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,800 employees, operating from 77 locations in 39 countries.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV